Meeting
2017 ASCO Annual Meeting
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
Authors
Amikar Sehdev
Indiana University, Indianapolis, IN
Amikar Sehdev , Yuanyuan Zha , Theodore G. Karrison , Linda A. Janisch , Ezra E.W. Cohen , Michael L. Maitland , Blase N. Polite , Michelle Turcich , Gini F. Fleming , Ravi Salgia , Navin R. Pinto , Thomas Gajewski , Marc Bissonnette , Mark J. Ratain , Manish Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Clinical Trial Registration Number
NCT02145559
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS11628)
DOI
10.1200/JCO.2017.35.15_suppl.TPS11628
Abstract #
TPS11628
Poster Bd #
326b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
First Author: Niamh Coleman
Poster
2021 ASCO Annual Meeting
Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.
First Author: Nigel Waters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
First Author: Sun Young Rha
Poster
2019 ASCO Annual Meeting
A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.
First Author: David S. Hong